Active substance
Results for the substance brigatinib
4 results
About this active substance
Brigatinib is a medication used for the treatment of advanced or metastatic non-small cell lung cancer (NSCLC) with ALK (anaplastic lymphoma kinase) gene mutations. It is an ALK kinase inhibitor that blocks abnormal cellular signaling contributing to the growth and spread of cancer cells.
The medication is taken orally, usually once daily, as directed by a doctor. The dosage may be adjusted based on the patient's tolerance and response to treatment.
Common side effects include nausea, vomiting, fatigue, muscle pain, and elevated liver enzyme levels. In rare cases, more severe adverse effects such as pneumonitis or high blood pressure may occur.
Brigatinib is not recommended for pregnant or breastfeeding women, as it may affect fetal development. Patients should inform their doctor about all medications they are taking to avoid drug interactions.
The medication is taken orally, usually once daily, as directed by a doctor. The dosage may be adjusted based on the patient's tolerance and response to treatment.
Common side effects include nausea, vomiting, fatigue, muscle pain, and elevated liver enzyme levels. In rare cases, more severe adverse effects such as pneumonitis or high blood pressure may occur.
Brigatinib is not recommended for pregnant or breastfeeding women, as it may affect fetal development. Patients should inform their doctor about all medications they are taking to avoid drug interactions.
-
-
ALUNBRIG 180mg film-coated tablets TAKEDA ORIGINAL MEDICINE
-
ALUNBRIG 90mg film-coated tablets TAKEDA ORIGINAL MEDICINE
-
ALUNBRIG 30mg film-coated tablets TAKEDA ORIGINAL MEDICINE